Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag FDA approves new fast, convenient treatment for advanced follicular lymphoma.

flag The FDA has approved Genentech’s Lunsumio VELO for treating adults with relapsed or refractory follicular lymphoma after two or more prior therapies. flag The subcutaneous injection, given in one minute, replaces a previous IV infusion that took up to four hours. flag Clinical data showed a 75% objective response rate and 59% complete response rate. flag The new method offers faster treatment and improved patient convenience.

5 Articles

Further Reading